Regado Biosciences and Spectrum Pharmaceuticals Join Forces in Leading the 2nd Annual Chief Medical Officer Summit

The Conference Forum announces Dr. Lee Allen, Spectrum Pharmaceuticals and Dr. Steven Zelenkofkse, Regado Biosciences as Co-Chairs for the 2nd Annual Chief Medical Officer Summit for Emerging Biotechs at the Ritz-Carlton in Boston on May 5-6, 2014.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The Chief Medical Officer Summit is the highlight of the year. It is a great opportunity to share best practices and network with CMOs across the industry.

New York, New York (PRWEB) March 17, 2014

Dr. Allen and Dr. Zelenkofske provide a framework to the 2014 summit in their opening remarks by defining the role of the CMO, which can differ radically from organization to organization. In the summit’s Keynote Case Study, Dr. Jakob Dupont of OncoMed presents insights on the Life of a CMO Pre- and Post-IPO to kick off the event.

Designed to address both the outward and inward facing challenges of emerging life science Chief Medical Officers, the 2014 CMO Summit offers discussions on positioning drugs for regulatory approval and reimbursement; working through complex contracts; career development opportunities; what CEOs look for in a CMO; and how investors determine the valuation of biotechs. A mentoring session for aspiring CMOs will also be hosted for MDs.

“The multiplicity of challenges facing CMOs today, as they help to strategically maneuver their organizations through the increasing complexity of drug development and commercialization, continues to grow. While this may seem daunting, how better to arm yourself to successfully address these unique challenges than by sharing perspectives and insights with your industry colleagues?” says co-chair, Dr Lee Allen, Spectrum Pharmaceuticals.

Co-Chair, Steven Zelenkofkse added, "The Chief Medical Officer Summit is the highlight of the year. It is a great opportunity to share best practices and network with CMOs across the industry."

Participating companies include: AcelRx; Aptiv Solutions; Arisaph; Alzheon; Crescendo/Myriad Genetics; Dynogen; Esperion; Halloran Consulting Group; Idera; Moderna; MP Healthcare Venture Management; OncoMed; Pharmacyclics; Rapid; Regado Biosciences; Rhythm; SDG LLC; Spectrum; SR One; Tufts CSDD; Willow Tree Capital; Zalicus.

About the Chief Medical Officer Summit:
The Chief Medical Officer Summit was created from an idea suggested by Dr. Elizabeth Stoner of MPM Capital about the need for a forum specific to CMOs of small to mid-sized biotechs. The summit aims to address the unique challenges of these Life Science CMOs and to form a community where they can share ideas, solutions and support.

About The Conference Forum
The Conference Forum has a very specific focus – developing specialized events both public and private as well as research groups and advisory boards for professionals in the life science industry. Its mission is to create the best content in an ideal forum for the exchange of ideas among peers and networking for Pharmaceutical and Biotech professionals. See more at: http://theconferenceforum.org/.


Contact

Follow us on: Contact's Twitter